IRMD Stock Analysis: Iradimed | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 1.231m USD | 12M Return: 65.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 13.3M
EPS Trend: 97.0%
Qual. Beats: 2
Rev. Trend: 99.7%
Qual. Beats: 5
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
IRADIMED CORPORATION is a medical device company specializing in MRI-compatible equipment, including intravenous infusion pump systems (MRidium 3870 and 3860+) and patient vital signs monitoring systems (3880), along with related accessories such as non-magnetic IV poles, dose error reduction systems, and ferromagnetic detection devices. Founded in 1992 and headquartered in Orlando, Florida, the company serves hospitals, acute care facilities, and outpatient imaging centers through a mix of direct sales representatives, regional sales directors, clinical application specialists, and independent distributors across the United States and internationally.
As a small-cap player within the Health Care Equipment sub-industry, IRADIMED operates in a focused niche of the medical device market. Its products are engineered specifically to operate safely within the strong magnetic fields of MRI suites, addressing a specialized need that limits competition from conventional infusion and monitoring equipment manufacturers. The company went public on the NASDAQ in July 2014 and maintains a concentrated product portfolio centered on patient safety and clinical workflow efficiency during MRI procedures.
- MRI procedure volume recovery drives pump system orders
- Disposable IV tubing set sales expand recurring revenue margins
- New 3880 patient monitoring system adoption accelerates hospital contract wins
| Net Income: 23.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.21 > 0.02 and ΔFCF/TA 7.31 > 1.0 |
| NWC/Revenue: 86.12% < 20% (prev 88.70%; Δ -2.58% < -1%) |
| CFO/TA 0.25 > 3% & CFO 28.9m > Net Income 23.6m |
| Net Debt/EBITDA: error (cannot be calculated) |
| Current Ratio: 7.13 > 1.5 & < 3 |
| Outstanding Shares: last quarter (12.9m) vs 12m ago 0.35% < -2% |
| Gross Margin: 76.84% > 18% (prev 76.91%; Δ -0.08% > 0.5%) |
| Asset Turnover: 79.85% > 50% (prev 73.88%; Δ 5.97% > 0%) |
| Interest Coverage Ratio: 100.0k > 6 (EBIT TTM 30.2m / Interest Expense TTM 3.0) |
| A: 0.65 (Total Current Assets 86.4m - Total Current Liabilities 12.1m) / Total Assets 114.4m |
| B: 0.59 (Retained Earnings 67.5m / Total Assets 114.4m) |
| C: 0.28 (EBIT TTM 30.2m / Avg Total Assets 108.1m) |
| D: 6.21 (Book Value of Equity 98.5m / Total Liabilities 15.9m) |
| Altman-Z'' = 14.58 = AAA |
| DSRI: 0.92 (Receivables 13.4m/12.7m, Revenue 86.3m/75.2m) |
| GMI: 1.00 (GM 76.91% / 76.84%) |
| AQI: 0.54 (AQ_t 0.03 / AQ_t-1 0.06) |
| SGI: 1.15 (Revenue 86.3m / 75.2m) |
| TATA: -0.05 (NI 23.6m - CFO 28.9m) / TA 114.4m) |
| Beneish M = -3.26 (Cap -4..+1) = AA |
As of July 11, 2026, the stock is trading at USD 97.20 with a total of 88,908 shares traded. Over the past week, the price has changed by -3.73%, over one month by +1.25%, over three months by +4.31% and over the past year by +65.72%.
Current recommended Stop Loss: 92.40 (which is 4.9% or 1.3 ATR below the current price).
Iradimed has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy IRMD.
- StrongBuy: 1
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 118 | 21.4% |
P/E Trailing = 52.6284
P/E Forward = 41.1523
P/S = 14.2687
P/B = 13.1134
P/EG = 4.46
Revenue TTM = 86.3m USD
EBIT TTM = 30.2m USD
EBITDA TTM = 32.2m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 1.17b USD (1.23b + (null Debt) - CCE 56.4m)
Interest Coverage Ratio = 10.1m (Ebit TTM 30.2m / Interest Expense TTM 3.0)
EV/FCF = 48.75x (Enterprise Value 1.17b / FCF TTM 24.1m)
FCF Yield = 2.05% (FCF TTM 24.1m / Enterprise Value 1.17b)
FCF Margin = 27.93% (FCF TTM 24.1m / Revenue TTM 86.3m)
Net Margin = 27.36% (Net Income TTM 23.6m / Revenue TTM 86.3m)
Gross Margin = 76.84% ((Revenue TTM 86.3m - Cost of Revenue TTM 20.0m) / Revenue TTM)
Gross Margin QoQ = 76.50% (prev 75.06%)
Tobins Q-Ratio = 10.27 (Enterprise Value 1.17b / Total Assets 114.4m)
Interest Expense / Debt = unknown (Interest Expense 3.0 / Debt none)
Taxrate = 21.78% (6.57m / 30.2m)
NOPAT = 23.6m (EBIT 30.2m * (1 - 21.78%))
Current Ratio = 7.13 (Total Current Assets 86.4m / Total Current Liabilities 12.1m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 32.2m)
Debt / FCF = unknown (Net Debt none / FCF TTM 24.1m)
Total Stockholder Equity = 96.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 21.85% (Net Income 23.6m / Total Assets 114.4m)
RoE = 24.48% (Net Income TTM 23.6m / Total Stockholder Equity 96.4m)
RoCE = 29.51% (EBIT 30.2m / Capital Employed (Total Assets 114.4m - Current Liab 12.1m))
RoIC = 24.10% (NOPAT 23.6m / Invested Capital 98.0m)
WACC = 7.44% (E(1.23b)/V(1.23b) * Re(7.44%) + (debt-free company))
Discount Rate = 7.44% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 0.46%
[DCF] Terminal Value 77.97% ; FCFF base≈20.1m ; Y1≈23.0m ; Y5≈33.8m
[DCF] Fair Price = 39.84 (EV 509.2m - Net Debt 0.0 = Equity 509.2m / Shares 12.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 97.03 | EPS CAGR: 13.48% | SUE: 1.54 | # QB: 2
Revenue Correlation: 99.71 | Revenue CAGR: 13.38% | SUE: 2.04 | # QB: 5
EPS current Quarter (2026-06-30): EPS=0.44 | Chg30d=-5.38% | Revisions=-25% | Analysts=2
EPS next Quarter (2026-09-30): EPS=0.54 | Chg30d=-0.92% | Revisions=-25% | Analysts=2
EPS current Year (2026-12-31): EPS=2.08 | Chg30d=-0.24% | Revisions=+25% | GrowthEPS=+7.5% | GrowthRev=+8.8%
EPS next Year (2027-12-31): EPS=2.35 | Chg30d=+1.51% | Revisions=+0% | GrowthEPS=+13.5% | GrowthRev=+10.6%
[Analyst] Revisions Ratio: -17% (up=1, down=2)